Tag: Meta

Subzero Labs Emerges with $20M Raise to Build the First Real World Network

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- ...

Match, Collect, Win! Squishmallows Universe Expands With New Match Game

Pre-order or pre-register starting August 6th to unlock exclusive in-game rewards and be the first to collect a brand-new Squishmallows VANCOUVER, BC, Aug. 6, 2025...

Data Center Capex to Grow at 21 Percent CAGR Through 2029, According to Dell’Oro Group

Hyperscalers to Account for Half the $1.2 Trillion Global Data Center Capex by 2029 REDWOOD CITY, Calif., Aug. 6, 2025 /PRNewswire/ -- According to a...

OpenAI Lets the Genie Out Again

OpenAI just tossed out its first open-weight models in more than five years. The two models, gpt-oss-120b and gpt-oss-20b, can run locally on consumer...

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency

New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 5, 2025 /PRNewswire/ -- Bracco Imaging, a global...

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

ChatGPT Gets Rowdy, World Keeps Spinning

On today's rundown, we’ve got the usual suspects in tech hype: Meta throwing its checkbook at AI talent, the brain drain from pandemic stress,...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

On the 30th anniversary of the Netscape IPO the inventor of the banner ad warns: “Trouble ahead.”

Author of the new book, "How the Web Won", cautions that AI is showing clear signs it's upsetting the fundamentals of the $790 billion...

Get Ready: Why Nvidia’s 2025 Surge Could Boost Your Portfolio

Hey there, fabulous finance queens! 🌟 Let's dive into the world of AI and why it's making waves in the stock market. Today, we're...

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO

NEW YORK, July 31, 2025 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor....

Niio Launches Streaming Art & Signage Service, Bringing Curated Visual Art Experiences to Every Screen

Any screen. Any space. An always-on canvas for art, ambience, and digital culture

Any screen. Any space. An always-on canvas for art, ambience, and digital culture

ExiScale Earns 4.7-Star Trustpilot Rating, Strengthening Its Position as a Reliable Meta Ad Account Provider

Marketers turn to ExiScale for long-term stability, lifetime guarantees, and real human support amid rising Meta ad account bans

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsMeta

Syssero Named Workday Deployment Partner

VenHub Global Expands Autonomous Retail Platform into Florida

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma